



The University of Sydney
School of Public Health

Australian General Practice Statistics and Classification Centre
Family Medicine Research Centre



BEACH

BETTERING THE EVALUATION AND CARE OF HEALTH

Allopurinol

January 2005 – December 2005 (12 months data)

July 2011

Enquiries to: Helena Britt

Telephone: (02) 9845 8151

Explanatory notes for Problem Report

Background

This report represents a summary of the data collected from January 2005 until December 2005 inclusive. It provides information on the prescribing of allopurinol (CAPS code 'M302').

Each year, BEACH collects data from around 1,000 GPs, who each record details about 100 consecutive consultations, thus providing an annual database of approximately 100,000 records.

Summary of BEACH data

BEACH Year	Number of GPs	Number of encounters	Number of problems managed	Number of medications (prescribed, GP supplied, over the counter)	Number of prescribed medications
	Raw (weighted)	Raw (weighted)	Raw (weighted)	Raw (weighted)	Raw (weighted)
April 1998-March 1999	984 (969.0)	98,400 (96,900.9)	145,183 (140,823.7)	107,451 (106,320.0)	91,427 (90,709.9)
April 1999-March 2000	1047 (1048.6)	104,700 (104,856.3)	156,576 (153,857.1)	113,555 (115,431.5)	96,925 (98,371.8)
April 2000-March 2001	999 (993.1)	99,900 (99,307.3)	147,518 (143,528.3)	108,179 (107,399.6)	91,602 (91,647.2)
April 2001-March 2002	983 (969.7)	98,300 (96,972.9)	144,372 (139,091.8)	102,352 (101,349.9)	85,304 (85,332.1)
April 2002-March 2003	1008 (1009.9)	100,800 (100,987.0)	149,976 (146,335.7)	103,289 (104,813.3)	83,755 (85,161.4)
April 2003-March 2004	1000 (1000.0)	100,000 (98,876.7)	150,126 (144,674.0)	103,774 (103,210.1)	85,023 (85,073.4)
April 2004-March 2005	953 (954.0)	95,300 (94,385.8)	141,489 (137,329.9)	95,672 (95,816.3)	77,913 (78,711.1)
April 2005-March 2006	1017 (1017.3)	101,700 (101,993.0)	152,802 (149,087.9)	105,340 (106,492.6)	85,600 (87,543.6)
April 2006-March 2007	930 (930.0)	93,000 (91,804.7)	140,886 (136,333.2)	93,140 (93,193.5)	75,495 (76,430.4)
April 2007-March 2008	953 (953.1)	95,300 (95,897.7)	147,724 (145,078.0)	96,488 (98,439.3)	76,440 (79,051.3)
April 2008-March 2009	1011 (1011.1)	101,100 (96,687.7)	159,412 (149,462.2)	108,545 (102,737.1)	88,458 (83,509.4)
April 2009-March 2010	988 (988.4)	98,800 (101,349.0)	155,889 (155,372.6)	103,232 (108,000.6)	79,229 (84,539.5)

The participating GPs are randomly selected from the HIC list of active GPs (those who provided more than 375 GP services in the previous quarter). The research instrument used for each consultation is a single page recording form. An example of the recording forms can be found in Appendix 1 of the BEACH annual report, General practice activity in Australia 2008–09 <<http://www.aihw.gov.au/publications/gep/gep-25-11013/gep-25-11013-x00.pdf>>. The recording form contains the following variables:

- Date of encounter
- Medicare Benefits Schedule (MBS) item number (up to three)/form of payment/indirect encounters (e.g. telephone consults)
- Patient age and sex
- Patient status to practice (new or seen before)
- Health care card status of patient
- Patient post code and ethnic background
- Patient's reasons for encounter (up to three per encounter)
- Diagnoses/problems managed (up to four)
- Status of each problem to the patient (new/old)
- Whether problems are work related
- Medications prescribed (up to four per problem)
- Over the counter medications recommended
- Medications provided by the GP
- Name, strength and regimen of medication
- Number of repeats for medication
- Medication status - new or continued
- Other treatments (up to two per problem)
- Pathology tests ordered (up to five)
- Imaging ordered (up to two)
- Referrals and hospital admissions (up to two).

Statistical Analysis

The confidence interval (CI) is calculated as the rate estimate \pm (1.96 x standard error). The CI is interpreted as “we are 95% confident that the true population value lies between the lower and upper value”. Please note that in some cases, if there were less than three observations (n) in the row, no 95% CIs are provided as data were insufficient to calculate a meaningful estimate. The analysis used procedures in SAS v9.1 that calculate standard errors which adjust for the cluster survey design¹. Keep in mind when reading the report, where BEACH data are reported in a standard set of categories (e.g. types of Medicare claimable encounters), a missing category means there were no occurrences of the event (e.g. home visits missing indicates no home visits were done for this condition/group of conditions). Also, where the most common 30 or 60 cases are listed (e.g. most frequent patient reasons for encounter, table 3.4), only the 30 with the highest frequency of occurrence have been printed. While there may have been other cases with a lower frequency of occurrence, the list has been cut off at 30.

TABLE A: Summary of all medications – Allopurinol – Jan05-Dec05

This table provides the overall rated prescription/ GP supply of Allopurinol. It includes a count of the total number of prescriptions for Allopurinol during the time period, the prescription/supply rate for each generic within this group of drugs, and a breakdown of the rate at which the participating GPs recorded the script as a generic name and the relative rate of prescription of each of the product names for this generic. The prescribing rates are presented in terms of the rate per 100 BEACH encounters, the rate per 100 problems managed and the percentage of all medications that is accounted for by this medication. If the selected medication is a class of drugs then the percent of this class that is accounted for by each generic or specific product is listed in the column titled “% of Allopurinol”. The “% generic” column shows the percentage of a generic accounted for by each specific product.

The “national annual estimated meds” gives the estimated number of GP contacts where the specified medication was prescribed/supplied/advised in the selected year across Australia. It is calculated as [*the number of specified medications prescribed/supplied/advised (n) / the total number of recorded encounters within the specified study period*] X *the number of general practice consultations claimed from Medicare in the specified year*. If you have requested encounters for a selected patient characteristic/s (e.g. sex, age, state) this column will be restricted to the national annual estimate of consultations with those selected patient characteristic/s.

¹ SAS Institute. SAS/STAT® User's guide, Version 9.1. Cary, NC: SAS Institute Inc, 2003.

The table below lists the number of non-specialist GP Medicare services for each specified BEACH year (April-March)². If your report is based on multiple BEACH years (e.g. 2003–04 to 2005–06) the rate has been extrapolated to the average annual GP consultations over the multiple years E.g. (96,300,000+ 98,200,000 + 101,100,000) / 3.

	BEACH year	Annual GP consultations[^]
1	1998–99	102,600,000
2	1999–00	101,500,000
3	2000–01	100,600,000
4	2001–02	99,900,000
5	2002–03	96,900,000
6	2003–04	96,300,000
7	2004–05	98,200,000
8	2005–06	101,100,000
9	2006–07	103,400,000
10	2007–08	109,500,000
11	2008–09	113,000,000
12	2009–10	116,600,000
13	2010–11	118,100,000

[^]Annual GP consultations are rounded to the nearest 100,000.

Available online at : <http://www.health.gov.au/internet/main/publishing.nsf/Content/medstat-jun10-tablez>

Then select Group BA Tables - Selected Aggregates by Broad Type of Service and by Financial Year followed by Group B1A Tables – Number of Services

TABLE B: Summary of ‘new’ medications – Allopurinol – Jan05-Dec05

The above analysis is repeated for the Allopurinol which are classified as ‘new’. A *new medication* is one that is being prescribed/supplied/advised for the management of this problem in this patient for the first time.

² Medicare Australia. 2006. Medicare Benefits Schedule (MBS) statistics reports. <http://www.health.gov.au/internet/main/publishing.nsf/Content/medstat-mar08-tables-b>.

TABLE C: Summary of 'continued' medications – Allopurinol – Jan05-Dec05

The above analysis is repeated for the Allopurinol which are classified as 'continued'. A *continued medication* is one that is being prescribed/supplied/advised as a continuation or a repeat of a previous therapy for this problem.

SECTION 1: SUMMARY OF ENCOUNTERS

TABLE 1a: Type of encounter – Allopurinol – Jan05-Dec05

Definitions of the categories are as follows:

Encounter (enc): Any professional interchange between a patient and a GP.

Direct encounters: Encounters where there is a face-to-face meeting of the patient and the GP.

No charge: Encounters where no fee (Medicare bulk billing or other) is received for the service provided.

MBS items by GPs: Encounters claimable through the MBS. The following groups are claimable through the relevant MBS item numbers.

Short surgery consults: (Level A) A short encounter which requires limited examination and management.

Standard surgery consults: (Level B) An encounter of less than 20 minutes duration, which requires an examination of the patient and an implementation of a management plan in relation to at least one of the problems.

Long surgery consults: (Level C) An encounter with duration between 20 and 40 minutes, which involves taking a detailed history and implementing a management plan for at least one of the problems.

Prolonged surgery consults: (Level D) An encounter with a duration of more than 40 minutes, which involves taking an exhaustive history, a comprehensive examination, the arrangement of necessary investigations and implementing a management plan for at least one of the problems.

Home visits: Encounters that take place in the patient's home and a MBS home visit item number(s) are recorded.

Hospital: Encounters that take place with a patient in a hospital setting, and a MBS hospital item number(s) are recorded.

Residential aged care facility: Encounters that take place in a residential aged care facility (RACF) and an MBS RACF item number is recorded.

Case conferences: Encounters that are covered by a MBS item number for a case conference.

Chronic disease management: Encounters that are covered by a MBS chronic disease management item number(s).

GP mental health care: Encounters that are covered by a MBS GP mental health care plan item number(s).

Health assessments: Encounters that are covered by a MBS item number for a health assessment.

Incentive payments: Encounters where MBS incentive payment items are recorded.

Other items: Medicare item numbers that do not identify the place of encounter and are not covered by any of the above item numbers.

Worker's compensation: Encounters claimable through Worker's Compensation.

Other paid (hospital, state etc): All other direct services covered by other funding services e.g. insurance, employer, state health dept, hospitals, etc.

Direct encounters with practice nurse item only: Encounters where a practice nurse item number was the only item number recorded though the patient was said to have been seen by the GP.

Indirect encounters: Encounters where there is no face-to-face meeting between the patient and the GP but a service is provided (e.g. prescription, referral).

Indirect encounters with practice nurse item only: Encounters where a practice nurse item number was the only item number recorded, and the patient was said *not* to have been seen by the GP.

Unspecified practice nurse item only: Encounters where a practice nurse item number was the only item number recorded, and it is unknown whether the patient was/wasn't seen by the GP.

TABLE 1a 2: Summary of data base: services – Allopurinol – Jan05-Dec05

This table will only be valid if **all** of your data are from the period April 2005 onwards. If your data are based on years that cross April 2005, this table is not valid. This is because, prior to April 2005 only one item number could be recorded. From April 2005 onwards, up to three Medicare item numbers could be recorded on an encounter form. The denominator for the column titled "per 100 encs" is all encounters (from table 1a). This table is useful when allocating direct costs against management of a selected problem.

TABLE 1b: Summary of database: morbidity and management – Allopurinol – Jan05-Dec05

This table describes the characteristics of the problems and medications that are included in this report. Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

General practitioners is the number of GPs who recorded encounters that are included in this report (i.e. those who prescribed/supplied/advised Allopurinol within the specified data period).

Problem managed: A formal statement of the providers' understanding of a health problem presented by the patient, family or community. It can be described in terms of a disease, symptom/complaint, social problem or ill-defined condition managed at the encounter (up to four per encounter).

New problems: The first presentation of a problem, including the first presentation of a recurrence of a previously resolved problem but excluding the presentation of a problem first assessed by another provider.

Old problems: A previously assessed problem that requires ongoing care. Includes follow-up for a problem or an initial presentation of a problem previously assessed by another provider.

Chronic problem: A medical condition characterised by a combination of the following characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of recurrence or deterioration, a poor prognosis, and consequences that impact on an individual's quality of life.

Chronic problem: A medical condition not characterised by those characteristics listed above.

Work related: A problem that is viewed as having resulted or been significantly exacerbated from a work-related activity or workplace exposures.

Medications: The total number of the selected medication/s that are prescribed, advised for over-the-counter (OTC) purchase or provided from the GP's own supplies (GP supplied). Up to four medications can be recorded for each problem.

Prescribed: The total number of the selected medication/s that were prescribed by the GP.

GP supplied: The total number of the selected medication/s that were provided from the practice supplies e.g. sample or vaccine.

Advised OTC: The total number of the selected medication/s that were advised to be purchased over-the-counter i.e. an S2 or S3 product.

New: A medication that is prescribed/supplied/advised is being used for the management of the problem for the first time.

Continued: A medication that is prescribed/supplied/advised as a continuation or a repeat of previous therapy for the problem.

SECTION 2: GENERAL PRACTITIONERS

Tables 2.1 and 2.2 display the characteristics of the GPs who prescribed/supplied/advised Allopurinol at least once.

TABLE 2.1: General practitioners: age by sex – Allopurinol – Jan05-Dec05

This table displays the age-sex distribution of the GPs who were included in this analysis. These data were collected from the GP Profile Questionnaire which is completed by all GPs participating in the BEACH project (see Appendix 2 in BEACH annual report, General practice activity in Australia 2008–09, <<http://www.aihw.gov.au/publications/gep/gep-25-11013/gep-25-11013-x00.pdf>>).

TABLE 2.2: GP characteristics – Allopurinol – Jan05-Dec05

This table displays the characteristics of the GPs, collected from the GP Profile Questionnaire. Definitions of the categories are as follows:

Years in general practice: The number of years the GP has been in general practice.

Sessions: The number of sessions worked per week.

Practice size-Number of GPs at practice: The number of GPs in the participating GPs main practice (including the participating GP).

Practice size-FTE GPs at practice: The number of full time equivalent GPs in the participating GPs main practice (including the participating GP).

Practice state: The state which the GPs main practice is in.

RRMA of main practice (Rural, Remote & Metropolitan Area Classification) classifies the location of the practice to one of 7 categories <www.ruraldoc.com.au>.

ASGC of main practice (Australian Standard Geographical Classification) classifies the location of the practice to one of 5 categories <www.abs.gov.au>.

Country of Graduation: The GPs reported country of graduation.

>50% consults NESB: (non-English speaking background) the GPs assessment of the proportion of their consultations conducted in a language other than English.

Hold FRACGP is whether the participating GP is a Fellow of the Royal Australian College of General Practitioners.

Practice accredited is whether the practice is accredited.

SECTION 3: PATIENT CHARACTERISTICS

TABLE 3.1: Summary of database: patients – Allopurinol – Jan05-Dec05

This table describes the characteristics of the patients who received the selected medication at their encounter. Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

Sex and age distributions are provided. The age groupings correspond with significant trends in GP service use.

HCC card: Encounters with patients who hold an Australian Government health care card (HCC).

VA card: Encounters with Veteran's Affairs card holders (not necessarily charged through VA).

NESB: Encounters with patients whose primary language spoken at home is not English (non-English speaking background).

Aboriginal only: Patients who identify themselves as being Aboriginal and not Torres Strait Islander.

Torres Strait Islander only: Patients who identify themselves as being Torres Strait Islander and not Aboriginal.

Aboriginal & Torres Strait Islander: Patients who identify themselves as being both an Aboriginal and a Torres Strait Islander.

Aboriginal and/or TSI: Patients who are Aboriginal or Torres Strait Islanders, or both.

New to practice: Patients who had not been seen previously in this practice.

Seen previously: Patients who had been seen previously in this practice.

State/territory: The patients' state/territory is provided, based on the postcode reported by the patient.

RRMA (Rural, Remote & Metropolitan Areas classification) classifies the patients' locations to one of 7 categories <www.ruraldoc.com.au>.

ASGC (Australian Standard Geographical Classification) classifies the patients' locations to one of 5 categories <www.abs.gov.au>.

TABLE 3.2: Age by gender of patient at encounter – Allopurinol – Jan05-Dec05

This table displays the age-sex distribution of the patients that have been included in this analysis.

TABLE 3.3: Reasons for encounters (RFEs) – ICPC chapter – Allopurinol – Jan05-Dec05

Reasons for encounter (RFE) reflect the patients' expressed demand for care as perceived and recorded by the GP. Up to three RFEs can be recorded at each encounter. A RFE is not directly linked to a problem managed. This table gives the number of RFEs recorded for encounters where the selected medication was prescribed/supplied/advised. RFEs have been grouped using ICPC-2 PLUS chapter headings which correspond approximately to the main body systems with additional chapters for social and psychological problems. Problems which cross multiple body systems are grouped together as "General & unspecified".

Each RFE is coded using ICPC-2 PLUS and classified to ICPC-2. There are seventeen chapters in ICPC-2 which are mainly based on body systems.

Details on these chapters can be found at <www.fmrc.org.au/icpc2/tech.htm>.

This table shows the distribution of RFEs by ICPC-2 chapter at the encounters where Allopurinol were prescribed/supplied/advised.

TABLE 3.4: Most frequent patient reasons for encounter (RFEs) – Allopurinol – Jan05-Dec05

This table shows the 30 most common RFEs recorded at the encounters where Allopurinol were prescribed/supplied/advised. The RFE label is the individual ICPC rubric label unless denoted by *, which indicates a grouping of multiple ICPC rubrics under the same RFE (concept) label. Number of observations (n), % of total RFEs, rate per 100 encounters and 95% CIs are provided for each data point.

SECTION 4: ALL MEDICATIONS

TABLE 4.1: Medication source – Allopurinol – Jan05-Dec05

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase. Refer to notes on Table 1b for definitions of prescribed/supplied/advised medications). Medication source is of greatest interest where the selected medication can be either prescribed or advised (e.g. paracetamol). The data are presented in three levels –

Total prescribed/supplied/advised Allopurinol

Generic Allopurinol

Individual product recorded by the GP

At each level, the medication is expressed as the number of observations (n), as a percentage of the total Allopurinol that were prescribed/supplied/advised, and upper and lower CIs. The right section of the table shows the number that was prescribed/supplied/advised, and the percentage of each medication.

TABLE 4.2: Medication status – Allopurinol – Jan05-Dec05

This table displays the status of each medication as being either new or continued (refer to notes on Table 1b for definitions of new and continued), and these figures are expressed as a percentage of the total Allopurinol. The first three columns also appear in Table A and notes for these are provided in the explanatory notes for Table A. The right section of the table shows the number that was new/continued, and the percentage of each medication.

TABLE 4.3.1: Prescribed regimen – Allopurinol (generic level) – Jan05-Dec05

The prescribed regimen of the selected medication is presented in this table at generic level. “Prescribed regimen” includes prescribed, supplied and advised medications. The prescribed dose, units, quantity and frequency (quantity + frequency usually = number of times per day) are provided for each medication. The column labelled “% of generic group” represents the percentage of a generic accounted for by the medication with a particular regimen. It is calculated as $[the\ number\ of\ each\ generic\ with\ an\ exact\ regimen / the\ total\ number\ of\ a\ specific\ generic] \times 100$.

TABLE 4.3.2: Prescribed regimen – Allopurinol (product level) – Jan05-Dec05

The prescribed regimen of the selected medication is presented in this table at product level. Explanations for the columns parallel those in Table 4.3.2.

TABLE 4.4.1: Prescribed daily dose – Allopurinol (generic level) – Jan05-Dec05

Medications that are prescribed/supplied/advised by the GP, for which complete regimen and dosage (in micrograms, milligrams or grams) information are recorded, are included in the calculation of the prescribed daily dose (PDD). The number of medications (n) and the prescribed daily doses for each generic medication are shown. Complete dosage and regimen information are required for calculation of PDD. The column labelled “% of generic group” is calculated as: *[the number of each generic with this PDD/the total number of each generic with a valid PDD] X 100*.

TABLE 4.4.2: Prescribed daily dose – Allopurinol (product level) – Jan05-Dec05

The prescribed daily dose of the selected medication is presented in this table at product level. Explanations for the columns parallel those in Table 4.4.1.

TABLE 4.5: Average prescribed daily dose – Allopurinol – Jan05-Dec05

This table provides the mean PDD, median PDD, minimum and maximum PDD for the selected medication, at generic and product level. “Average prescribed daily dose” includes prescribed, supplied and advised medications. Note that the median is often a more reliable measure of central tendency than the mean, which is influenced by outliers.

TABLE 4.6: Average number of repeats – Allopurinol – Jan05-Dec05

For each problem managed with the selected medication this table provides the mean, median, minimum and maximum number of repeats, at generic and product level. Again note that the median is often a more reliable measure of central tendency than the average which is influenced by outliers.

SECTION 5: NEW MEDICATIONS

TABLE 5.1: Medication source – ‘new’ Allopurinol – Jan05-Dec05

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase (similar to Table 4.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.2: Medication status – ‘new’ Allopurinol – Jan05-Dec05

This table displays the status of each medication as being either new or continued (similar to Table 4.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.3.1: Prescribed regimen – ‘new’ Allopurinol (generic level) – Jan05-Dec05

This table displays the prescribed regimen of the selected medication at generic level (similar to Table 4.3.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.3.2: Prescribed regimen – ‘new’ Allopurinol (product level) – Jan05-Dec05

This table displays the prescribed regimen of the selected medication at product level (similar to Table 4.3.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.4.1: Prescribed daily dose – ‘new’ Allopurinol (generic level) – Jan05-Dec05

This table displays the prescribed daily dose of the selected medication at generic level (similar to Table 4.4.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.4.2: Prescribed daily dose – ‘new’ Allopurinol (product level) – Jan05-Dec05

This table displays the prescribed daily dose of the selected medication at product level (similar to Table 4.4.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.5: Average prescribed daily dose – ‘new’ Allopurinol – Jan05-Dec05

This table displays the average prescribed daily dose of the selected medication, at generic and product level (similar to Table 4.5) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.6: Average number of repeats – ‘new’ Allopurinol – Jan05-Dec05

This table displays the average number of repeats of the selected medication, at generic and product level (similar to Table 4.6) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

SECTION 6: CONTINUED MEDICATIONS**TABLE 6.1: Medication source – ‘continued’ Allopurinol – Jan05-Dec05**

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase (similar to Table 4.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.2: Medication status – ‘continued’ Allopurinol – Jan05-Dec05

This table displays the status of each medication as being either new or continued (similar to Table 4.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.3.1: Prescribed regimen – ‘continued’ Allopurinol (generic level) – Jan05-Dec05

This table displays the prescribed regimen of the selected medication at generic level (similar to Table 4.3.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.3.2: Prescribed regimen – ‘continued’ Allopurinol (product level) – Jan05-Dec05

This table displays the prescribed regimen of the selected medication at product level (similar to Table 4.3.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.4.1: Prescribed daily dose – ‘continued’ Allopurinol (generic level) – Jan05-Dec05

This table displays the prescribed daily dose of the selected medication at generic level (similar to Table 4.4.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.4.2: Prescribed daily dose – ‘continued’ Allopurinol (product level) – Jan05-Dec05

This table displays the prescribed daily dose of the selected medication at product level (similar to Table 4.4.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.5: Average prescribed daily dose – ‘continued’ Allopurinol – Jan05-Dec05

This table displays the average prescribed daily dose of the selected medication, at generic and product level (similar to Table 4.5) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.6: Average number of repeats – ‘continued’ Allopurinol – Jan05-Dec05

This table displays the average number of repeats of the selected medication, at generic and product level (similar to Table 4.6) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

SECTION 7: PROBLEMS MANAGED

TABLE 7.1.1: Problems managed – ICPC chapter – Allopurinol – Jan05-Dec05

This table described the distribution, by ICPC chapter, of all problems (includes all diagnoses, diseases, ill-defined conditions and complaints) for which the GP prescribed/supplied/advised the selected medication at the encounter. The column labelled “% of GPs” includes the proportion of all GPs within the data period who prescribed/supplied/advised at least one of the selected medications to manage the specific problem. “% of specific problem” includes the proportion of the specific problem managed with at least one of the selected medications at the encounter. Number of problems (n), % of Allopurinol problems, and 95% confidence interval (CI) are also provided for each data point.

TABLE 7.1.2: Problems managed – Allopurinol – Jan05-Dec05

This table described the distribution, by the individual ICPC rubric label, of all problems (includes all diagnoses, diseases, ill-defined conditions and complaints) for which the GP prescribed/supplied/advised the selected medication at the encounter. The asterisk (*) indicates a grouping of multiple

ICPC rubrics under the same problem (concept) label, e.g. “Hypertension*” groups the ICPC rubrics of Hypertension Uncomplicated (K86) and Hypertension Complicated (K87). (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2008–09, <<http://www.aihw.gov.au/publications/gep/gep-26-11014/gep-26-11014-x04.pdf>>).

The column labelled “% of GPs” includes the proportion of all GPs within the data period who prescribed/supplied/advised at least one of the selected medications to manage the specific problem. “% of specific problem” includes the proportion of the specific problem managed with at least one of the selected medications at the encounter. Number of problems (n), % of Allopurinol problems, and 95% confidence interval (CI) are also provided for each data point.

TABLE 7.2: Medication source by individual problem managed – Allopurinol – Jan05-Dec05

This table displays the method by which the medication was provided (similar to Table 4.1) by the problem managed. The right section of the table shows the number that was prescribed/supplied/advised, and the percentage of each problem (refer to notes on Table 1b for definitions of prescribed/supplied/advised medications).

TABLE 7.2.1: Medication source by individual problem managed – ‘New’ Allopurinol – Jan05-Dec05

This table displays the method by which the medication was provided (similar to Table 4.1) by the problem managed, for encounters where the medication was classified as ‘new’ (see definition Table 1b). The right section of the table shows the number of ‘new’ medications that were prescribed/supplied/advised, and the percentage of each problem (refer to notes on Table 1b for definitions of prescribed/supplied/advised medications).

TABLE 7.2.2: Medication source by individual problem managed – ‘Continued’ Allopurinol – Jan05-Dec05

This table displays the method by which the medication was provided (similar to Table 4.1) by the problem managed, for encounters where the medication was classified as ‘continued’ (see definition Table 1b). The right section of the table shows the number of ‘continued’ medications that were prescribed/supplied/advised, and the percentage of each problem (refer to notes on Table 1b for definitions of prescribed/supplied/advised medications).

TABLE 7.3: Medication status by individual problem managed – Allopurinol – Jan05-Dec05

This table displays the status of the selected medication (similar to Table 4.2) by the problem managed. The right section of the table shows the number that was new/continued, and the percentage of each problem (refer to notes on Table 1b for definitions).

TABLE 7.4: Prescribed regimen by individual problem managed for each generic – Allopurinol – Jan05-Dec05

The prescribed regimen of the selected medication is presented for each of the problems for which the selected medication was prescribed/supplied/advised (similar to Table 4.3.1).

TABLE 7.5: Prescribed daily dose by individual problem managed for each generic – Allopurinol – Jan05-Dec05

For each problem managed with the selected medication, this table provides the prescribed daily dose recorded by the GPs. For further notes refer to Table 4.4.1.

TABLE 7.6: Average prescribed daily dose by individual problem managed for each generic – Allopurinol – Jan05-Dec05

For each problem managed with the selected medication, this table provides the mean, median, minimum and maximum PDD recorded by the GPs. For further notes refer to Table 4.5.

TABLE 7.7: Average number of repeats by individual problem managed – Allopurinol – Jan05-Dec05

For each problem managed with the selected medication this table provides the mean, median, minimum and maximum number of repeats recorded by the GPs. For further notes refer to Table 4.6.

BEACH Survey Report - Analysis date: 05JUL11

Table A: Summary of all medications - Allopurinol Jan05-Dec05

Generic	Product	n	Rate per			Rate per			% of all Allopurinol	% of generic	National annual estimated meds	Lower 95% CI	Upper 95% CI
			100 all encs	Lower 95% CI	Upper 95% CI	100 probs	% of all meds						
Total Allopurinol		326	0.33	0.29	0.37	0.22	0.32	.	.	335300	294400	376200	
Allopurinol		326	0.33	0.29	0.37	0.22	0.32	100.00	.	335300	294400	376200	
	Allopurinol NOS	53	0.05	0.04	0.07	0.04	0.05	16.26	16.26	54500	38800	70200	
	Allopurinol capsules 100 mg	1	0.00	.	.	0.00	0.00	0.31	0.31	1000	.	.	
	Allopurinol capsules 300 mg	1	0.00	.	.	0.00	0.00	0.31	0.31	1000	.	.	
	Allopurinol tablets 100 mg	5	0.01	0.00	0.01	0.00	0.00	1.53	1.53	5100	600	9600	
	Allopurinol tablets 300 mg	7	0.01	0.00	0.01	0.00	0.01	2.15	2.15	7200	0	15000	
	Progout NOS	3	0.00	0.00	0.01	0.00	0.00	0.92	0.92	3100	0	6600	
	Progout tablets 100 mg	19	0.02	0.01	0.03	0.01	0.02	5.83	5.83	19500	9900	29100	
	Progout tablets 300 mg	67	0.07	0.05	0.08	0.05	0.06	20.55	20.55	68900	52200	85600	
	Capurate capsules 300 mg	1	0.00	.	.	0.00	0.00	0.31	0.31	1000	.	.	
	Allosig tablets 300 mg	1	0.00	.	.	0.00	0.00	0.31	0.31	1000	.	.	
	Zyloprim NOS	4	0.00	0.00	0.01	0.00	0.00	1.23	1.23	4100	0	9100	
	Zyloprim tablets 100 mg	40	0.04	0.03	0.05	0.03	0.04	12.27	12.27	41100	27400	54900	
	Zyloprim tablets 300 mg	123	0.13	0.10	0.15	0.08	0.12	37.73	37.73	126500	102500	150500	
	Allohexal tablets 100 mg	1	0.00	.	.	0.00	0.00	0.31	0.31	1000	.	.	

Refer to explanatory notes for the base used in calculation of national annual estimated medications,
and the number of estimated medications is rounded to the nearest 100.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 98300 and 148216 respectively.

BEACH Survey Report - Analysis date: 05JUL11

Table B: Summary of 'new' medications - Allopurinol Jan05-Dec05

Generic	Product	n	Rate per			Rate per			% of all meds	% of Allopurinol	% of generic	National annual estimated meds	Lower 95% CI	Upper 95% CI
			100 all encs	Lower 95% CI	Upper 95% CI	100 probs	Lower 95% CI	Upper 95% CI						
Total Allopurinol		36	0.04	0.02	0.05	0.02	0.03	.	.		37000	22400	51700	
Allopurinol		36	0.04	0.02	0.05	0.02	0.03	100.00	.		37000	22400	51700	
	Allopurinol NOS	11	0.01	0.00	0.02	0.01	0.01	30.56	30.56		11300	4100	18600	
	Allopurinol tablets 300 mg	3	0.00	0.00	0.01	0.00	0.00	8.33	8.33		3100	0	9100	
	Progout tablets 100 mg	1	0.00	.	.	0.00	0.00	2.78	2.78		1000	.	.	
	Progout tablets 300 mg	2	0.00	.	.	0.00	0.00	5.56	5.56		2100	.	.	
	Zyloprim tablets 100 mg	11	0.01	0.00	0.02	0.01	0.01	30.56	30.56		11300	3500	19100	
	Zyloprim tablets 300 mg	8	0.01	0.00	0.01	0.01	0.01	22.22	22.22		8200	2500	13900	

Refer to explanatory notes for the base used in calculation of national annual estimated medications,
and the number of estimated medications is rounded to the nearest 100.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 98300 and 148216 respectively.

BEACH Survey Report - Analysis date: 05JUL11

Table C: Summary 'continued' medications - Allopurinol Jan05-Dec05

Generic	Product	n	Rate per			Rate per			% of all Allopurinol	% of generic	National annual estimated meds	Lower 95% CI	Upper 95% CI
			100 all encs	Lower 95% CI	Upper 95% CI	100 probs	% of all meds						
Total Allopurinol		290	0.30	0.26	0.33	0.20	0.28	.	.	298300	259600	336900	
Allopurinol		290	0.30	0.26	0.33	0.20	0.28	100.00	.	298300	259600	336900	
	Allopurinol NOS	42	0.04	0.03	0.06	0.03	0.04	14.48	14.48	43200	29200	57200	
	Allopurinol capsules 100 mg	1	0.00	.	.	0.00	0.00	0.34	0.34	1000	.	.	
	Allopurinol capsules 300 mg	1	0.00	.	.	0.00	0.00	0.34	0.34	1000	.	.	
	Allopurinol tablets 100 mg	5	0.01	0.00	0.01	0.00	0.00	1.72	1.72	5100	600	9600	
	Allopurinol tablets 300 mg	4	0.00	0.00	0.01	0.00	0.00	1.38	1.38	4100	0	9100	
	Progout NOS	3	0.00	0.00	0.01	0.00	0.00	1.03	1.03	3100	0	6600	
	Progout tablets 100 mg	18	0.02	0.01	0.03	0.01	0.02	6.21	6.21	18500	9100	27900	
	Progout tablets 300 mg	65	0.07	0.05	0.08	0.04	0.06	22.41	22.41	66900	50600	83100	
	Capurate capsules 300 mg	1	0.00	.	.	0.00	0.00	0.34	0.34	1000	.	.	
	Allosig tablets 300 mg	1	0.00	.	.	0.00	0.00	0.34	0.34	1000	.	.	
	Zyloprim NOS	4	0.00	0.00	0.01	0.00	0.00	1.38	1.38	4100	0	9100	
	Zyloprim tablets 100 mg	29	0.03	0.02	0.04	0.02	0.03	10.00	10.00	29800	18700	40900	
	Zyloprim tablets 300 mg	115	0.12	0.09	0.14	0.08	0.11	39.66	39.66	118300	94800	141800	
	Allohexal tablets 100 mg	1	0.00	.	.	0.00	0.00	0.34	0.34	1000	.	.	

Refer to explanatory notes for the base used in calculation of national annual estimated medications, and the number of estimated medications is rounded to the nearest 100.

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 98300 and 148216 respectively.

Table 1a: Type of encounter - Allopurinol Jan05-Dec05

Data	n	%	Lower 95% CI	Upper 95% CI
General practitioners	250	.	.	.
Encounters	326	.	.	.
Direct encounters	294	96.39	94.3	98.5
No charge	2	0.66	0.0	1.6
MBS items by GPs	292	95.74	93.5	98.0
- Short surgery consultations	4	1.31	0.0	2.6
- Standard surgery consultations	238	78.03	73.3	82.8
- Long surgery consultations	39	12.79	9.0	16.6
- Home or institution visits (not RACF)	6	1.97	0.4	3.5
- Residential aged care facility (RACF)	2	0.66	0.0	1.6
- Health assessments	1	0.33	0.0	1.0
- Incentive payments	2	0.66	0.0	1.6
Indirect encounters	11	3.61	1.5	5.7
Missing	21	.	.	.

The indirect encounters with item numbers (eg: chronic disease management item or case conference item) are counted under both MBS items by GPs and indirect encounters. Therefore, the number of no charge, medicare paid, worker's compensation and other paid do not always add up to the number of direct encounters.

During the BEACH study period April 1998 to March 2005, GPs were instructed to record the lowest Medicare item number (e.g.: an A1 item number) if multiple item numbers applied.

From April 2005 onwards, multiple Medicare item numbers (up to 3) could be recorded on an encounter form. The lowest item in the encounter was selected and analysed in this table. This provides comparable results to those reported before April 2005.

BEACH Survey Report - Analysis date: 05JUL11

Table 1b: Summary of database: morbidity and management - Allopurinol Jan05-Dec05

Data	n	Per 100 probs	Lower 95% CI	Upper 95% CI
General practitioners	250	.	.	.
Encounters	326	.	.	.
Reasons for encounter	608	.	.	.
Problems managed	326	.	.	.
- New problems	27	8.28	5.05	11.51
- Old problems	299	91.72	88.49	94.95
- Chronic problem	259	79.45	74.44	84.45
- Non-chronic problem	67	20.55	15.55	25.56
Medications	326	100.00	100.00	100.00
- Prescribed	319	97.85	96.30	99.40
- GP supplied	7	2.15	0.60	3.70
- Advised OTC	0	0.00	.	.
- New	36	11.04	6.90	15.20
- Continued	290	88.96	84.80	93.10

Table 2.1: General practitioners: age by sex - Allopurinol Jan05-Dec05

The FREQ Procedure

Table of gpage by gpsex

gpage(GP age)		gpsex(GP sex)		
Frequency		Male	Female	Total
Percent				
Row Pct				
Col Pct				
< 35 years	4	3	7	
	1.62	1.21	2.83	
	57.14	42.86		
	2.04	5.88		
35-44 years	23	12	35	
	9.31	4.86	14.17	
	65.71	34.29		
	11.73	23.53		
45-54 years	63	19	82	
	25.51	7.69	33.20	
	76.83	23.17		
	32.14	37.25		
55+ years	106	17	123	
	42.91	6.88	49.80	
	86.18	13.82		
	54.08	33.33		
Total	196	51	247	
	79.35	20.65	100.00	

Frequency Missing = 3

BEACH Survey Report - Analysis date: 05JUL11

Table 2.2: GP characteristics - Allopurinol Jan05-Dec05

Data	n	%
Years in general practice	.	.
<2 years	1.0	0.4
2-5 years	6.0	2.4
6-10 years	20.0	8.1
11-19 years	45.0	18.1
20+ years	176.0	71.0
Missing	2.0	.
Sessions^	.	.
< 5 per week	17.0	6.8
6-10 per week	202.0	80.8
11+ per week	31.0	12.4
Practice size-Num GPs at practice*	.	.
Missing	250.0	.
Practice size-FTE GPs at practice**	.	.
Missing	250.0	.
Practice state	.	.
ACT	3.0	1.2
NSW	108.0	43.2
VIC	37.0	14.8
QLD	46.0	18.4
SA	20.0	8.0
WA	23.0	9.2
TAS	6.0	2.4
NT	7.0	2.8
RRMA of main practice	.	.
Capital	165.0	66.0
Oth Met	18.0	7.2
Lge Rur	10.0	4.0
Sm Rur	18.0	7.2
Oth Rur	34.0	13.6
Rem Cen	2.0	0.8
Oth Rem, Offsh	3.0	1.2

^ Number of sessions worked per week not collected after Mar09

* Practice size-Num GPs at practice not collected between Apr07-Mar09

** Practice size-FTE GPs at practice not collected prior to Apr07

BEACH Survey Report - Analysis date: 05JUL11

Table 2.2: GP characteristics - Allopurinol Jan05-Dec05

Data	n	%
ASGC of main practice	.	.
Major Cities	179.0	71.6
Inner Regional	42.0	16.8
Outer Regional	24.0	9.6
Remote	4.0	1.6
Very Remote	1.0	0.4
	.	.
Country of graduation	.	.
Australia	175.0	70.0
New Zealand	2.0	0.8
Asia	36.0	14.4
UK/Ireland	20.0	8.0
Europe	6.0	2.4
Africa	10.0	4.0
Pacific	1.0	0.4
	.	.
> 50% consults NESB	.	.
Yes	12.0	4.8
No	237.0	95.2
Missing	1.0	.
	.	.
Hold FRACGP	.	.
Yes	77.0	31.2
No	170.0	68.8
Missing	3.0	.
	.	.
Practice Accredited	.	.
Yes	193.0	77.5
No	56.0	22.5
Missing	1.0	.
	.	.

^ Number of sessions worked per week not collected after Mar09

* Practice size-Num GPs at practice not collected between Apr07-Mar09

** Practice size-FTE GPs at practice not collected prior to Apr07

BEACH Survey Report - Analysis date: 05JUL11

Table 3.1: Summary of database: patients - Allopurinol Jan05-Dec05

Data	n	%	Lower 95% CI	Upper 95% CI
Patients	326	.	.	.
- Males	265	81.79	77.3	86.3
- Females	59	18.21	13.7	22.7
- Missing sex	2	.	.	.
- 5-14 years	1	0.31	0.0	0.9
- 25-44 years	23	7.12	4.3	9.9
- 45-64 years	132	40.87	35.4	46.4
- 65-74 years	84	26.01	21.2	30.8
- 75+ years	83	25.70	20.9	30.5
- Missing age	3	.	.	.
- HCC card	173	57.28	51.2	63.4
- No HCC card	129	42.72	36.6	48.8
- Missing HCC	24	.	.	.
- VA card	19	6.38	3.5	9.2
- No VA card	279	93.62	90.8	96.5
- Missing VA	28	.	.	.
- NESB	32	10.74	6.8	14.7
- English speaking background	266	89.26	85.3	93.2
- Missing NESB status	28	.	.	.
- Aboriginal and/or TSI	4	1.34	0.0	2.7
- Non-indigenous	294	98.66	97.3	100.0
- Missing ATSI status	28	.	.	.
- New to practice	8	2.52	0.8	4.2
- Seen previously	310	97.48	95.8	99.2
- Missing status	8	.	.	.

BEACH Survey Report - Analysis date: 05JUL11

Table 3.1: Summary of database: patients - Allopurinol Jan05-Dec05

Data	n	%	Lower 95% CI	Upper 95% CI
- ACT	4	1.27	0.0	2.8
- NSW	145	45.89	38.9	52.9
- VIC	48	15.19	10.1	20.3
- QLD	55	17.41	12.3	22.5
- SA	24	7.59	4.0	11.2
- WA	28	8.86	5.0	12.7
- TAS	6	1.90	0.4	3.4
- NT	6	1.90	0.4	3.4
- Missing state	10	.	.	.

RRMA- Capital	207	65.51	59.0	72.0
- Other Metro	25	7.91	4.2	11.6
- Large Rural	12	3.80	1.3	6.2
- Small Rural	20	6.33	3.0	9.6
- Other Rural	46	14.56	9.6	19.5
- Remote Central	2	0.63	0.0	1.5
- Other remote, Offshore	4	1.27	0.0	2.5
- Missing rrma	10	.	.	.

ASGC- Major Cities	221	70.16	63.9	76.4
- Inner Regional	57	18.10	13.0	23.2
- Outer Regional	32	10.16	5.8	14.5
- Remote	3	0.95	0.0	2.0
- Very Remote	2	0.63	0.0	1.5
- Missing ASGC	11	.	.	.

Table 3.2: Age by sex of patient at encounter - Allopurinol Jan05-Dec05

The FREQ Procedure

Table of sex by agegp

sex(Sex of patient) agegp(Patient Age-group)

Frequency						
Percent						
Row Pct						
Col Pct	5-14	25-44	45-64	65-74	75+	Total
Male	1	21	115	67	58	262
	0.31	6.54	35.83	20.87	18.07	81.62
	0.38	8.02	43.89	25.57	22.14	
	100.00	91.30	87.12	81.71	69.88	
Female	0	2	17	15	25	59
	0.00	0.62	5.30	4.67	7.79	18.38
	0.00	3.39	28.81	25.42	42.37	
	0.00	8.70	12.88	18.29	30.12	
Total	1	23	132	82	83	321
	0.31	7.17	41.12	25.55	25.86	100.00

Frequency Missing = 5

BEACH Survey Report - Analysis date: 05JUL11

Table 3.3: Reasons for encounters (RFEs)- ICPC chapter - Allopurinol Jan05-Dec05

RFE chapter	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
General & unspecified	214	35.20	65.64	57.6	73.7
Endocrine & metabolic	122	20.07	37.42	31.2	43.6
Circulatory	84	13.82	25.77	20.9	30.7
Musculoskeletal	62	10.20	19.02	14.3	23.7
Respiratory	35	5.76	10.74	7.2	14.3
Skin	33	5.43	10.12	6.5	13.7
Psychological	12	1.97	3.68	1.5	5.9
Blood	9	1.48	2.76	1.0	4.5
Urology	9	1.48	2.76	1.0	4.5
Ear	6	0.99	1.84	0.4	3.3
Neurological	6	0.99	1.84	0.4	3.3
Male genital system	6	0.99	1.84	0.4	3.3
Digestive	5	0.82	1.53	0.2	2.9
Eye	2	0.33	0.61	.	.
Social	2	0.33	0.61	.	.
Female genital system	1	0.16	0.31	.	.
.
Subtotal	608	100.00	.	.	.
.
Total RFEs	608	100.00	186.50	176.9	196.1

BEACH Survey Report - Analysis date: 05JUL11

Table 3.4: Most frequent patient reasons for encounters (RFEs) - Allopurinol Jan05-Dec05

RFE label	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
Prescription all*	193	31.74	59.20	51.8	66.6
Gout	48	7.89	14.72	10.8	18.7
Cardiac check-up*	33	5.43	10.12	6.8	13.5
Test results*	27	4.44	8.28	5.1	11.5
General check-up*	21	3.45	6.44	3.7	9.2
Hypertension*	18	2.96	5.52	2.9	8.1
Preventive immun/vacc/meds-all*	16	2.63	4.91	2.6	7.3
Foot/toe symptom/complaint	16	2.63	4.91	2.3	7.5
Joint symptom/complaint NOS	10	1.64	3.07	0.8	5.3
Blood test NOS	8	1.32	2.45	0.6	4.3
Back complaint*	7	1.15	2.15	0.6	3.7
Diabetes*	7	1.15	2.15	0.6	3.7
Cough	7	1.15	2.15	0.6	3.7
Blood test blood/lymph	6	0.99	1.84	0.4	3.3
Swelling*	6	0.99	1.84	0.4	3.3
Follow-up encounter unspecified cardiovascular	6	0.99	1.84	0.4	3.3
Knee symptom/complaint	6	0.99	1.84	0.4	3.3
Follow-up encounter unspecified NOS	5	0.82	1.53	0.2	2.9
Swollen ankles/oedema	5	0.82	1.53	0.2	2.9
Sleep disturbance	5	0.82	1.53	0.0	3.1
Follow-up encounter unspecified endocrine/metabolic	5	0.82	1.53	0.2	2.9
Administrative procedure NOS	4	0.66	1.23	0.0	2.4
Other reason for encounter NEC NOS	4	0.66	1.23	0.0	2.4
Skin check-up*	4	0.66	1.23	0.0	2.4
Endocrinology check-up*	4	0.66	1.23	0.0	2.4
Lipid disorders*	4	0.66	1.23	0.0	2.4
Vertigo/dizziness	4	0.66	1.23	0.0	2.4
Other referrals NEC NOS	3	0.49	0.92	0.0	2.0
Osteoarthritis*	3	0.49	0.92	0.0	2.0
Shortness of breath/dyspnoea	3	0.49	0.92	0.0	2.0
Subtotal	488	80.26	.	.	.
Other RFEs	120	19.74	.	.	.
Total RFEs	608	100.00	186.50	176.9	196.1

* Includes multiple ICD-10 or ICD-10 PLUS codes (see Appendix 5, <www.aihw.gov.au/publications/index.cfm/subject/19>).

BEACH Survey Report - Analysis date: 05JUL11

Table 4.1: Medication source - Allopurinol Jan05-Dec05

Generic	Product	n	% of Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		326	100.0	.	.	319	97.9	.	.	7	2.1
Allopurinol		326	100.0	100.0	100.0	319	97.9	.	.	7	2.1
	Allopurinol NOS	53	16.3	12.0	20.6	52	98.1	.	.	1	1.9
	Allopurinol capsules 100 mg	1	0.3	.	.	1	100.0
	Allopurinol capsules 300 mg	1	0.3	.	.	1	100.0
	Allopurinol tablets 100 mg	5	1.5	0.2	2.9	5	100.0
	Allopurinol tablets 300 mg	7	2.1	0.0	4.4	5	71.4	.	.	2	28.6
	Progout NOS	3	0.9	0.0	2.0	3	100.0
	Progout tablets 100 mg	19	5.8	3.1	8.6	19	100.0
	Progout tablets 300 mg	67	20.6	16.1	25.0	66	98.5	.	.	1	1.5
	Capurate capsules 300 mg	1	0.3	.	.	1	100.0
	Allosig tablets 300 mg	1	0.3	.	.	1	100.0
	Zyloprim NOS	4	1.2	0.0	2.7	4	100.0
	Zyloprim tablets 100 mg	40	12.3	8.4	16.1	39	97.5	.	.	1	2.5
	Zyloprim tablets 300 mg	123	37.7	32.2	43.3	121	98.4	.	.	2	1.6
	Allohexal tablets 100 mg	1	0.3	.	.	1	100.0

BEACH Survey Report - Analysis date: 05JUL11

Table 4.2: Medication status - Allopurinol Jan05-Dec05

Generic	Product	n	% of Allopurinol	% of generic	New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		326	100.0	.	36	11.0	290	89.0
Allopurinol		326	100.0	.	36	11.0	290	89.0
	Allopurinol NOS	53	16.3	16.26	11	20.8	42	79.2
	Allopurinol capsules 100 mg	1	0.3	0.31	.	.	1	100.0
	Allopurinol capsules 300 mg	1	0.3	0.31	.	.	1	100.0
	Allopurinol tablets 100 mg	5	1.5	1.53	.	.	5	100.0
	Allopurinol tablets 300 mg	7	2.1	2.15	3	42.9	4	57.1
	Progout NOS	3	0.9	0.92	.	.	3	100.0
	Progout tablets 100 mg	19	5.8	5.83	1	5.3	18	94.7
	Progout tablets 300 mg	67	20.6	20.55	2	3.0	65	97.0
	Capurate capsules 300 mg	1	0.3	0.31	.	.	1	100.0
	Allosig tablets 300 mg	1	0.3	0.31	.	.	1	100.0
	Zyloprim NOS	4	1.2	1.23	.	.	4	100.0
	Zyloprim tablets 100 mg	40	12.3	12.27	11	27.5	29	72.5
	Zyloprim tablets 300 mg	123	37.7	37.73	8	6.5	115	93.5
	Allohexal tablets 100 mg	1	0.3	0.31	.	.	1	100.0

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

BEACH Survey Report - Analysis date: 05JUL11

Table 4.3.1 : Prescribed regimen* - Allopurinol (generic level) Jan05-Dec05

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	7	.		.		2.1
Allopurinol	4	.		1	daily	1.2
Allopurinol	1	10	mg	3	daily	0.3
Allopurinol	1	50	mg	.		0.3
Allopurinol	1	50	mg	1	daily	0.3
Allopurinol	58	100	mg	1	daily	17.8
Allopurinol	6	100	mg	2	daily	1.8
Allopurinol	5	150	mg	1	daily	1.5
Allopurinol	19	200	mg	1	daily	5.8
Allopurinol	1	200	mg	2	daily	0.3
Allopurinol	3	300	mg	.		0.9
Allopurinol	216	300	mg	1	daily	66.3
Allopurinol	2	300	mg	2	daily	0.6
Allopurinol	1	400	mg	1	daily	0.3
Allopurinol	1	600	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 05JUL11

Table 4.3.2 : Prescribed regimen* - Allopurinol (product level) Jan05-Dec05

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	.		.		0.3
Allopurinol NOS	2	.		1	daily	0.6
Allopurinol NOS	1	10	mg	3	daily	0.3
Allopurinol NOS	13	100	mg	1	daily	4.0
Allopurinol NOS	1	100	mg	2	daily	0.3
Allopurinol NOS	6	200	mg	1	daily	1.8
Allopurinol NOS	28	300	mg	1	daily	8.6
Allopurinol NOS	1	400	mg	1	daily	0.3
Allopurinol capsules 100 mg	1	200	mg	1	daily	0.3
Allopurinol capsules 300 mg	1	300	mg	1	daily	0.3
Allopurinol tablets 100 mg	2	100	mg	1	daily	0.6
Allopurinol tablets 100 mg	1	100	mg	2	daily	0.3
Allopurinol tablets 100 mg	2	200	mg	1	daily	0.6
Allopurinol tablets 300 mg	1	150	mg	1	daily	0.3
Allopurinol tablets 300 mg	6	300	mg	1	daily	1.8
Progout NOS	3	.		.		0.9
Progout tablets 100 mg	14	100	mg	1	daily	4.3
Progout tablets 100 mg	4	200	mg	1	daily	1.2
Progout tablets 100 mg	1	200	mg	2	daily	0.3
Progout tablets 300 mg	2	.		1	daily	0.6
Progout tablets 300 mg	1	150	mg	1	daily	0.3
Progout tablets 300 mg	62	300	mg	1	daily	19.0
Progout tablets 300 mg	1	300	mg	2	daily	0.3
Progout tablets 300 mg	1	600	mg	1	daily	0.3
Capurate capsules 300 mg	1	300	mg	1	daily	0.3
Allosig tablets 300 mg	1	300	mg	1	daily	0.3
Zyloprim NOS	1	.		.		0.3
Zyloprim NOS	1	100	mg	1	daily	0.3
Zyloprim NOS	2	300	mg	1	daily	0.6
Zyloprim tablets 100 mg	1	.		.		0.3
Zyloprim tablets 100 mg	1	50	mg	.		0.3
Zyloprim tablets 100 mg	1	50	mg	1	daily	0.3
Zyloprim tablets 100 mg	27	100	mg	1	daily	8.3
Zyloprim tablets 100 mg	4	100	mg	2	daily	1.2
Zyloprim tablets 100 mg	6	200	mg	1	daily	1.8

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 05JUL11

Table 4.3.2 : Prescribed regimen* - Allopurinol (product level) Jan05-Dec05

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Zyloprim tablets 300 mg	1	.		.		0.3
Zyloprim tablets 300 mg	3	150	mg	1	daily	0.9
Zyloprim tablets 300 mg	3	300	mg	.		0.9
Zyloprim tablets 300 mg	115	300	mg	1	daily	35.3
Zyloprim tablets 300 mg	1	300	mg	2	daily	0.3
Allohexal tablets 100 mg	1	100	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 05JUL11

Table 4.4.1 : Prescribed daily dose* - Allopurinol (generic level) Jan05-Dec05

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	1	30	mg	0.3
Allopurinol	1	50	mg	0.3
Allopurinol	58	100	mg	18.6
Allopurinol	5	150	mg	1.6
Allopurinol	25	200	mg	8.0
Allopurinol	216	300	mg	69.5
Allopurinol	2	400	mg	0.6
Allopurinol	3	600	mg	1.0

*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen
and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 4.4.2 : Prescribed daily dose* - Allopurinol (product level) Jan05-Dec05

Product	n	Prescribed daily dose	Units	% of generic group
Allopurinol NOS	1	30	mg	0.3
Allopurinol NOS	13	100	mg	4.2
Allopurinol NOS	7	200	mg	2.3
Allopurinol NOS	28	300	mg	9.0
Allopurinol NOS	1	400	mg	0.3
Allopurinol capsules 100 mg	1	200	mg	0.3
Allopurinol capsules 300 mg	1	300	mg	0.3
Allopurinol tablets 100 mg	2	100	mg	0.6
Allopurinol tablets 100 mg	3	200	mg	1.0
Allopurinol tablets 300 mg	1	150	mg	0.3
Allopurinol tablets 300 mg	6	300	mg	1.9
Progout tablets 100 mg	14	100	mg	4.5
Progout tablets 100 mg	4	200	mg	1.3
Progout tablets 100 mg	1	400	mg	0.3
Progout tablets 300 mg	1	150	mg	0.3
Progout tablets 300 mg	62	300	mg	19.9
Progout tablets 300 mg	2	600	mg	0.6
Capurate capsules 300 mg	1	300	mg	0.3
Allosig tablets 300 mg	1	300	mg	0.3
Zyloprim NOS	1	100	mg	0.3
Zyloprim NOS	2	300	mg	0.6
Zyloprim tablets 100 mg	1	50	mg	0.3
Zyloprim tablets 100 mg	27	100	mg	8.7
Zyloprim tablets 100 mg	10	200	mg	3.2
Zyloprim tablets 300 mg	3	150	mg	1.0
Zyloprim tablets 300 mg	115	300	mg	37.0
Zyloprim tablets 300 mg	1	600	mg	0.3
Allohexal tablets 100 mg	1	100	mg	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 4.5: Average prescribed daily dose* - Allopurinol Jan05-Dec05

Generic	Product	n	Mean PDD	Measure	Median PDD	Measure	Minimum	Measure	Maximum	Measure
Allopurinol		311.00	254.1	mg	300	mg	30	mg	600	mg
	Allopurinol NOS	50.00	230.6	mg	300	mg	30	mg	400	mg
	Allopurinol capsules 100 mg	1.00	200.0	mg	200	mg	200	mg	200	mg
	Allopurinol capsules 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Allopurinol tablets 100 mg	5.00	160.0	mg	200	mg	100	mg	200	mg
	Allopurinol tablets 300 mg	7.00	278.6	mg	300	mg	150	mg	300	mg
	Progout tablets 100 mg	19.00	136.8	mg	100	mg	100	mg	400	mg
	Progout tablets 300 mg	65.00	306.9	mg	300	mg	150	mg	600	mg
	Capurate capsules 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Allosig tablets 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Zyloprim NOS	3.00	233.3	mg	300	mg	100	mg	300	mg
	Zyloprim tablets 100 mg	38.00	125.0	mg	100	mg	50	mg	200	mg
	Zyloprim tablets 300 mg	119.00	298.7	mg	300	mg	150	mg	600	mg
	Allohexal tablets 100 mg	1.00	100.0	mg	100	mg	100	mg	100	mg

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen
 and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 4.6: Average number of repeats - Allopurinol Jan05-Dec05

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		272.00	1.9	2	0	5
	Allopurinol NOS	40.00	1.6	2	0	2
	Allopurinol capsules 100 mg	1.00	2.0	2	2	2
	Allopurinol capsules 300 mg	1.00	2.0	2	2	2
	Allopurinol tablets 100 mg	5.00	2.2	2	0	5
	Allopurinol tablets 300 mg	6.00	2.0	2	2	2
	Progout tablets 100 mg	18.00	1.6	2	0	5
	Progout tablets 300 mg	59.00	2.0	2	0	5
	Allosig tablets 300 mg	1.00	2.0	2	2	2
	Zyloprim NOS	2.00	2.0	2	2	2
	Zyloprim tablets 100 mg	29.00	1.5	2	0	5
	Zyloprim tablets 300 mg	109.00	2.1	2	0	5
	Allohexal tablets 100 mg	1.00	2.0	2	2	2

BEACH Survey Report - Analysis date: 05JUL11

Table 5.1: Medication source - 'new' Allopurinol Jan05-Dec05

Generic	Product	n	% of 'new' Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		36	100.0	.	.	35	97.2	.	.	1	2.8
Allopurinol		36	100.0	100.0	100.0	35	97.2	.	.	1	2.8
	Allopurinol NOS	11	30.6	13.9	47.2	10	90.9	.	.	1	9.1
	Allopurinol tablets 300 mg	3	8.3	0.0	24.0	3	100.0
	Progout tablets 100 mg	1	2.8	.	.	1	100.0
	Progout tablets 300 mg	2	5.6	.	.	2	100.0
	Zyloprim tablets 100 mg	11	30.6	11.5	49.6	11	100.0
	Zyloprim tablets 300 mg	8	22.2	6.8	37.6	8	100.0

BEACH Survey Report - Analysis date: 05JUL11

Table 5.2: Medication status - 'new' Allopurinol Jan05-Dec05

Generic	Product	n	% of 'new' Allopurinol	% of generic		New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		36	100.0	.		36	100	.	.
Allopurinol		36	100.0	.		36	100	.	.
	Allopurinol NOS	11	30.6	30.56		11	100	.	.
	Allopurinol tablets 300 mg	3	8.3	8.33		3	100	.	.
	Progout tablets 100 mg	1	2.8	2.78		1	100	.	.
	Progout tablets 300 mg	2	5.6	5.56		2	100	.	.
	Zyloprim tablets 100 mg	11	30.6	30.56		11	100	.	.
	Zyloprim tablets 300 mg	8	22.2	22.22		8	100	.	.

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

Table 5.3.1 : Prescribed regimen* - 'new' Allopurinol (generic level) Jan05-Dec05

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	1	.		1	daily	2.8
Allopurinol	1	50	mg	.		2.8
Allopurinol	1	50	mg	1	daily	2.8
Allopurinol	13	100	mg	1	daily	36.1
Allopurinol	3	200	mg	1	daily	8.3
Allopurinol	17	300	mg	1	daily	47.2

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 05JUL11

Table 5.3.2 : Prescribed regimen* - 'new' Allopurinol (product level) Jan05-Dec05

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	.		1	daily	2.8
Allopurinol NOS	5	100	mg	1	daily	13.9
Allopurinol NOS	1	200	mg	1	daily	2.8
Allopurinol NOS	4	300	mg	1	daily	11.1
Allopurinol tablets 300 mg	3	300	mg	1	daily	8.3
Progout tablets 100 mg	1	100	mg	1	daily	2.8
Progout tablets 300 mg	2	300	mg	1	daily	5.6
Zyloprim tablets 100 mg	1	50	mg	.		2.8
Zyloprim tablets 100 mg	1	50	mg	1	daily	2.8
Zyloprim tablets 100 mg	7	100	mg	1	daily	19.4
Zyloprim tablets 100 mg	2	200	mg	1	daily	5.6
Zyloprim tablets 300 mg	8	300	mg	1	daily	22.2

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 5.4.1 : Prescribed daily dose* - 'new' Allopurinol (generic level) Jan05-Dec05

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	1	50	mg	2.9
Allopurinol	13	100	mg	38.2
Allopurinol	3	200	mg	8.8
Allopurinol	17	300	mg	50.0

*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen
and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 5.4.2 : Prescribed daily dose* - 'new' Allopurinol (product level) Jan05-Dec05

Product	n	Prescribed daily dose	Units	% of generic group
Allopurinol NOS	5	100	mg	14.7
Allopurinol NOS	1	200	mg	2.9
Allopurinol NOS	4	300	mg	11.8
Allopurinol tablets 300 mg	3	300	mg	8.8
Progout tablets 100 mg	1	100	mg	2.9
Progout tablets 300 mg	2	300	mg	5.9
Zyloprim tablets 100 mg	1	50	mg	2.9
Zyloprim tablets 100 mg	7	100	mg	20.6
Zyloprim tablets 100 mg	2	200	mg	5.9
Zyloprim tablets 300 mg	8	300	mg	23.5

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen
and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 5.5: Average prescribed daily dose* - 'new' Allopurinol Jan05-Dec05

Generic	Product	n	Mean	Measure	Median	Measure	Minimum	Measure	Maximum	Measure
			PDD		PDD					
Allopurinol		34.00	207.4	mg	250	mg	50	mg	300	mg
	Allopurinol NOS	10.00	190.0	mg	150	mg	100	mg	300	mg
	Allopurinol tablets 300 mg	3.00	300.0	mg	300	mg	300	mg	300	mg
	Progout tablets 100 mg	1.00	100.0	mg	100	mg	100	mg	100	mg
	Progout tablets 300 mg	2.00	300.0	mg	300	mg	300	mg	300	mg
	Zyloprim tablets 100 mg	10.00	115.0	mg	100	mg	50	mg	200	mg
	Zyloprim tablets 300 mg	8.00	300.0	mg	300	mg	300	mg	300	mg

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 5.6: Average number of repeats - 'new' Allopurinol Jan05-Dec05

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		33.00	1.5	2.0	0	5
	Allopurinol NOS	10.00	0.8	0.5	0	2
	Allopurinol tablets 300 mg	3.00	2.0	2.0	2	2
	Progout tablets 100 mg	1.00	0.0	0.0	0	0
	Progout tablets 300 mg	2.00	1.5	1.5	1	2
	Zyloprim tablets 100 mg	10.00	1.3	1.5	0	2
	Zyloprim tablets 300 mg	7.00	2.6	2.0	0	5

BEACH Survey Report - Analysis date: 05JUL11

Table 6.1: Medication source - 'continued' Allopurinol Jan05-Dec05

Generic	Product	n	% of 'continued' Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		290	100.0	.	.	284	97.9	.	.	6	2.1
Allopurinol		290	100.0	100.0	100.0	284	97.9	.	.	6	2.1
	Allopurinol NOS	42	14.5	10.1	18.9	42	100.0
	Allopurinol capsules 100 mg	1	0.3	.	.	1	100.0
	Allopurinol capsules 300 mg	1	0.3	.	.	1	100.0
	Allopurinol tablets 100 mg	5	1.7	0.2	3.2	5	100.0
	Allopurinol tablets 300 mg	4	1.4	0.0	3.0	2	50.0	.	.	2	50.0
	Progout NOS	3	1.0	0.0	2.2	3	100.0
	Progout tablets 100 mg	18	6.2	3.2	9.2	18	100.0
	Progout tablets 300 mg	65	22.4	17.6	27.2	64	98.5	.	.	1	1.5
	Capurate capsules 300 mg	1	0.3	.	.	1	100.0
	Allosig tablets 300 mg	1	0.3	.	.	1	100.0
	Zyloprim NOS	4	1.4	0.0	3.0	4	100.0
	Zyloprim tablets 100 mg	29	10.0	6.5	13.5	28	96.6	.	.	1	3.4
	Zyloprim tablets 300 mg	115	39.7	33.8	45.5	113	98.3	.	.	2	1.7
	Allohexal tablets 100 mg	1	0.3	.	.	1	100.0

BEACH Survey Report - Analysis date: 05JUL11

Table 6.2: Medication status - 'continued' Allopurinol Jan05-Dec05

Generic	Product	n	% of 'continued' Allopurinol	% of generic	New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		290	100.0	.	.	.	290	100
Allopurinol		290	100.0	.	.	.	290	100
	Allopurinol NOS	42	14.5	14.48	.	.	42	100
	Allopurinol capsules 100 mg	1	0.3	0.34	.	.	1	100
	Allopurinol capsules 300 mg	1	0.3	0.34	.	.	1	100
	Allopurinol tablets 100 mg	5	1.7	1.72	.	.	5	100
	Allopurinol tablets 300 mg	4	1.4	1.38	.	.	4	100
	Progout NOS	3	1.0	1.03	.	.	3	100
	Progout tablets 100 mg	18	6.2	6.21	.	.	18	100
	Progout tablets 300 mg	65	22.4	22.41	.	.	65	100
	Capurate capsules 300 mg	1	0.3	0.34	.	.	1	100
	Allosig tablets 300 mg	1	0.3	0.34	.	.	1	100
	Zyloprim NOS	4	1.4	1.38	.	.	4	100
	Zyloprim tablets 100 mg	29	10.0	10.00	.	.	29	100
	Zyloprim tablets 300 mg	115	39.7	39.66	.	.	115	100
	Allohexal tablets 100 mg	1	0.3	0.34	.	.	1	100

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

BEACH Survey Report - Analysis date: 05JUL11

Table 6.3.1 : Prescribed regimen* - 'continued' Allopurinol (generic level) Jan05-Dec05

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	7	.		.		2.4
Allopurinol	3	.		1	daily	1.0
Allopurinol	1	10	mg	3	daily	0.3
Allopurinol	45	100	mg	1	daily	15.5
Allopurinol	6	100	mg	2	daily	2.1
Allopurinol	5	150	mg	1	daily	1.7
Allopurinol	16	200	mg	1	daily	5.5
Allopurinol	1	200	mg	2	daily	0.3
Allopurinol	3	300	mg	.		1.0
Allopurinol	199	300	mg	1	daily	68.6
Allopurinol	2	300	mg	2	daily	0.7
Allopurinol	1	400	mg	1	daily	0.3
Allopurinol	1	600	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 05JUL11

Table 6.3.2 : Prescribed regimen* - 'continued' Allopurinol (product level) Jan05-Dec05

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	.		.		0.3
Allopurinol NOS	1	.		1	daily	0.3
Allopurinol NOS	1	10	mg	3	daily	0.3
Allopurinol NOS	8	100	mg	1	daily	2.8
Allopurinol NOS	1	100	mg	2	daily	0.3
Allopurinol NOS	5	200	mg	1	daily	1.7
Allopurinol NOS	24	300	mg	1	daily	8.3
Allopurinol NOS	1	400	mg	1	daily	0.3
Allopurinol capsules 100 mg	1	200	mg	1	daily	0.3
Allopurinol capsules 300 mg	1	300	mg	1	daily	0.3
Allopurinol tablets 100 mg	2	100	mg	1	daily	0.7
Allopurinol tablets 100 mg	1	100	mg	2	daily	0.3
Allopurinol tablets 100 mg	2	200	mg	1	daily	0.7
Allopurinol tablets 300 mg	1	150	mg	1	daily	0.3
Allopurinol tablets 300 mg	3	300	mg	1	daily	1.0
Progout NOS	3	.		.		1.0
Progout tablets 100 mg	13	100	mg	1	daily	4.5
Progout tablets 100 mg	4	200	mg	1	daily	1.4
Progout tablets 100 mg	1	200	mg	2	daily	0.3
Progout tablets 300 mg	2	.		1	daily	0.7
Progout tablets 300 mg	1	150	mg	1	daily	0.3
Progout tablets 300 mg	60	300	mg	1	daily	20.7
Progout tablets 300 mg	1	300	mg	2	daily	0.3
Progout tablets 300 mg	1	600	mg	1	daily	0.3
Capurate capsules 300 mg	1	300	mg	1	daily	0.3
Allosig tablets 300 mg	1	300	mg	1	daily	0.3
Zyloprim NOS	1	.		.		0.3
Zyloprim NOS	1	100	mg	1	daily	0.3
Zyloprim NOS	2	300	mg	1	daily	0.7
Zyloprim tablets 100 mg	1	.		.		0.3
Zyloprim tablets 100 mg	20	100	mg	1	daily	6.9
Zyloprim tablets 100 mg	4	100	mg	2	daily	1.4
Zyloprim tablets 100 mg	4	200	mg	1	daily	1.4
Zyloprim tablets 300 mg	1	.		.		0.3
Zyloprim tablets 300 mg	3	150	mg	1	daily	1.0

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 05JUL11

Table 6.3.2 : Prescribed regimen* - 'continued' Allopurinol (product level) Jan05-Dec05

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Zyloprim tablets 300 mg	3	300	mg	.		1.0
Zyloprim tablets 300 mg	107	300	mg	1	daily	36.9
Zyloprim tablets 300 mg	1	300	mg	2	daily	0.3
Allohexal tablets 100 mg	1	100	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 6.4.1 : Prescribed daily dose* - 'continued' Allopurinol (generic level) Jan05-Dec05

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	1	30	mg	0.4
Allopurinol	45	100	mg	16.2
Allopurinol	5	150	mg	1.8
Allopurinol	22	200	mg	7.9
Allopurinol	199	300	mg	71.8
Allopurinol	2	400	mg	0.7
Allopurinol	3	600	mg	1.1

*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen
and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 6.4.2 : Prescribed daily dose* - 'continued' Allopurinol (product level) Jan05-Dec05

Product	n	Prescribed daily dose	Units	% of generic group
Allopurinol NOS	1	30	mg	0.4
Allopurinol NOS	8	100	mg	2.9
Allopurinol NOS	6	200	mg	2.2
Allopurinol NOS	24	300	mg	8.7
Allopurinol NOS	1	400	mg	0.4
Allopurinol capsules 100 mg	1	200	mg	0.4
Allopurinol capsules 300 mg	1	300	mg	0.4
Allopurinol tablets 100 mg	2	100	mg	0.7
Allopurinol tablets 100 mg	3	200	mg	1.1
Allopurinol tablets 300 mg	1	150	mg	0.4
Allopurinol tablets 300 mg	3	300	mg	1.1
Progout tablets 100 mg	13	100	mg	4.7
Progout tablets 100 mg	4	200	mg	1.4
Progout tablets 100 mg	1	400	mg	0.4
Progout tablets 300 mg	1	150	mg	0.4
Progout tablets 300 mg	60	300	mg	21.7
Progout tablets 300 mg	2	600	mg	0.7
Capurate capsules 300 mg	1	300	mg	0.4
Allosig tablets 300 mg	1	300	mg	0.4
Zyloprim NOS	1	100	mg	0.4
Zyloprim NOS	2	300	mg	0.7
Zyloprim tablets 100 mg	20	100	mg	7.2
Zyloprim tablets 100 mg	8	200	mg	2.9
Zyloprim tablets 300 mg	3	150	mg	1.1
Zyloprim tablets 300 mg	107	300	mg	38.6
Zyloprim tablets 300 mg	1	600	mg	0.4
Allohexal tablets 100 mg	1	100	mg	0.4

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen
and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 6.5: Average prescribed daily dose* - 'continued' Allopurinol Jan05-Dec05

Generic	Product	n	Mean PDD	Measure	Median PDD	Measure	Minimum	Measure	Maximum	Measure
Allopurinol		277.00	259.9	mg	300	mg	30	mg	600	mg
	Allopurinol NOS	40.00	240.8	mg	300	mg	30	mg	400	mg
	Allopurinol capsules 100 mg	1.00	200.0	mg	200	mg	200	mg	200	mg
	Allopurinol capsules 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Allopurinol tablets 100 mg	5.00	160.0	mg	200	mg	100	mg	200	mg
	Allopurinol tablets 300 mg	4.00	262.5	mg	300	mg	150	mg	300	mg
	Progout tablets 100 mg	18.00	138.9	mg	100	mg	100	mg	400	mg
	Progout tablets 300 mg	63.00	307.1	mg	300	mg	150	mg	600	mg
	Capurate capsules 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Allosig tablets 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Zyloprim NOS	3.00	233.3	mg	300	mg	100	mg	300	mg
	Zyloprim tablets 100 mg	28.00	128.6	mg	100	mg	100	mg	200	mg
	Zyloprim tablets 300 mg	111.00	298.6	mg	300	mg	150	mg	600	mg
	Allohexal tablets 100 mg	1.00	100.0	mg	100	mg	100	mg	100	mg

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 6.6: Average number of repeats - 'continued' Allopurinol Jan05-Dec05

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		239.00	2.0	2	0	5
	Allopurinol NOS	30.00	1.8	2	0	2
	Allopurinol capsules 100 mg	1.00	2.0	2	2	2
	Allopurinol capsules 300 mg	1.00	2.0	2	2	2
	Allopurinol tablets 100 mg	5.00	2.2	2	0	5
	Allopurinol tablets 300 mg	3.00	2.0	2	2	2
	Progout tablets 100 mg	17.00	1.7	2	0	5
	Progout tablets 300 mg	57.00	2.0	2	0	5
	Allosig tablets 300 mg	1.00	2.0	2	2	2
	Zyloprim NOS	2.00	2.0	2	2	2
	Zyloprim tablets 100 mg	19.00	1.6	2	0	5
	Zyloprim tablets 300 mg	102.00	2.1	2	0	5
	Allohexal tablets 100 mg	1.00	2.0	2	2	2

BEACH Survey Report - Analysis date: 05JUL11

Table 7.1.1: Problems managed- ICPC chapter - Allopurinol Jan05-Dec05

Problem label	n probs	% of GPs*	% of Allopurinol problems	Lower 95% CI	Upper 95% CI	% of specific problem**
Endocrine & metabolic	258	21.46	79.14	74.13	84.15	2.15
General & unspecified	37	2.95	11.35	7.15	15.55	0.23
Circulatory	11	1.02	3.37	1.22	5.53	0.06
Musculoskeletal	9	0.92	2.76	1.02	4.50	0.05
Urology	7	0.71	2.15	0.57	3.73	0.23
Blood	2	0.20	0.61	.	.	0.13
Digestive	1	0.10	0.31	.	.	0.01
Male genital system	1	0.10	0.31	.	.	0.06
.
Total problems	326	.	100.00	.	.	.

* The Proportion of all GPs within the data period prescribed, advised or supplied at least one selected medication to manage the specific problem.
 ** Proportion of specific problem managed with at least one selected medication at the encounter.

Table 7.1.2: Problems managed - Allopurinol Jan05-Dec05

Problem label	n probs	% of GPs**	% of Allopurinol problems	Lower 95% CI	Upper 95% CI	% of specific problem***
Gout	236	19.94	72.39	67.07	77.72	41.40
Prescription all*	32	2.54	9.82	5.82	13.81	1.51
Endocrine/metabolic/nutritional disease, other	15	1.42	4.60	2.20	7.00	2.54
Hypertension*	7	0.61	2.15	0.35	3.95	0.07
Diabetes*	5	0.51	1.53	0.19	2.88	0.15
Arthritis (excl. OA and rheumatoid)*	4	0.41	1.23	0.05	2.41	0.64
Preventive immun/vacc/meds-all*	4	0.20	1.23	0.00	3.12	0.07
Urinary calculus	3	0.31	0.92	0.00	1.96	2.56
Osteoarthritis*	2	0.20	0.61	.	.	0.07
Limited function/disability NOS	1	0.10	0.31	.	.	1.20
General symptom/complaint, other	1	0.10	0.31	.	.	0.58
Benign/uncertain neoplasm blood/lymph	1	0.10	0.31	.	.	3.85
Blood/lymph/spleen disease, other	1	0.10	0.31	.	.	1.27
Oesophagus disease	1	0.10	0.31	.	.	0.04
Back complaint*	1	0.10	0.31	.	.	0.04
General check-up*	1	0.10	0.31	.	.	0.04
Abnormal test results*	1	0.10	0.31	.	.	0.12
Lipid disorders*	1	0.10	0.31	.	.	0.03
Limited function/disability cardiovascular	1	0.10	0.31	.	.	25.00
Rheumatic fever/heart disease	1	0.10	0.31	.	.	7.14
Heart failure	1	0.10	0.31	.	.	0.15
Elevated blood pressure	1	0.10	0.31	.	.	0.49
Joint symptom/complaint NOS	1	0.10	0.31	.	.	0.37
Haematuria	1	0.10	0.31	.	.	0.69
Limited function/disability urinary	1	0.10	0.31	.	.	4.76
Urinary disease, other	1	0.10	0.31	.	.	1.15
Prostatitis/seminal vesiculitis	1	0.10	0.31	.	.	1.96
Total problems	326	.	100.00	.	.	.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The Proportion of all GPs within the data period prescribed, advised or supplied at least one selected medication to manage the specific problem.

*** Poportion of specific problem managed with at least one selected medication at the encounter.

Table 7.2: Medication source by individual problem managed - Allopurinol Jan05-Dec05

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol	Prescribed n	% of meds for specific prob	Advised n	% of meds for specific prob	GP supplied n	% of meds for specific prob
Gout	236	72.4	230	97.5	.	.	6	2.5
Prescription all*	32	9.8	32	100.0
Endocrine/metabolic/nutritional disease, other	15	4.6	14	93.3	.	.	1	6.7
Hypertension*	7	2.1	7	100.0
Diabetes*	5	1.5	5	100.0
Arthritis (excl. OA and rheumatoid)*	4	1.2	4	100.0
Preventive immun/vacc/meds-all*	4	1.2	4	100.0
Urinary calculus	3	0.9	3	100.0
Osteoarthritis*	2	0.6	2	100.0
Limited function/disability NOS	1	0.3	1	100.0
General symptom/complaint, other	1	0.3	1	100.0
Benign/uncertain neoplasm blood/lymph	1	0.3	1	100.0
Blood/lymph/spleen disease, other	1	0.3	1	100.0
Oesophagus disease	1	0.3	1	100.0
Back complaint*	1	0.3	1	100.0
General check-up*	1	0.3	1	100.0
Abnormal test results*	1	0.3	1	100.0
Lipid disorders*	1	0.3	1	100.0
Limited function/disability cardiovascular	1	0.3	1	100.0
Rheumatic fever/heart disease	1	0.3	1	100.0
Heart failure	1	0.3	1	100.0
Elevated blood pressure	1	0.3	1	100.0
Joint symptom/complaint NOS	1	0.3	1	100.0
Haematuria	1	0.3	1	100.0
Limited function/disability urinary	1	0.3	1	100.0
Urinary disease, other	1	0.3	1	100.0
Prostatitis/seminal vesiculitis	1	0.3	1	100.0
	=====		=====		=====		=====	
	326		319		0		7	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

BEACH Survey Report - Analysis date: 05JUL11

Table 7.2.1: Medication source by individual problem managed - 'New' Allopurinol Jan05-Dec05

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol	Prescribed n	% of meds for specific prob	Advised n	% of meds for specific prob	GP supplied n	% of meds for specific prob
Gout	27	75.0	26	96.3	.	.	1	3.7
Prescription all*	2	5.6	2	100.0
Endocrine/metabolic/nutritional disease, other	2	5.6	2	100.0
Arthritis (excl. OA and rheumatoid)*	1	2.8	1	100.0
Osteoarthritis*	1	2.8	1	100.0
Abnormal test results*	1	2.8	1	100.0
Joint symptom/complaint NOS	1	2.8	1	100.0
Prostatitis/seminal vesiculitis	1	2.8	1	100.0
	=====		=====		=====		=====	
	36		35		0		1	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

Table 7.2.2: Medication source by individual problem managed - 'Continued' Allopurinol Jan05-Dec05

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol	Prescribed n	% of meds for specific prob	Advised n	% of meds for specific prob	GP supplied n	% of meds for specific prob
Gout	209	72.1	204	97.6	.	.	5	2.4
Prescription all*	30	10.3	30	100.0
Endocrine/metabolic/nutritional disease, other	13	4.5	12	92.3	.	.	1	7.7
Hypertension*	7	2.4	7	100.0
Diabetes*	5	1.7	5	100.0
Preventive immun/vacc/meds-all*	4	1.4	4	100.0
Arthritis (excl. OA and rheumatoid)*	3	1.0	3	100.0
Urinary calculus	3	1.0	3	100.0
Limited function/disability NOS	1	0.3	1	100.0
General symptom/complaint, other	1	0.3	1	100.0
Benign/uncertain neoplasm blood/lymph	1	0.3	1	100.0
Blood/lymph/spleen disease, other	1	0.3	1	100.0
Oesophagus disease	1	0.3	1	100.0
Back complaint*	1	0.3	1	100.0
General check-up*	1	0.3	1	100.0
Osteoarthritis*	1	0.3	1	100.0
Lipid disorders*	1	0.3	1	100.0
Limited function/disability cardiovascular	1	0.3	1	100.0
Rheumatic fever/heart disease	1	0.3	1	100.0
Heart failure	1	0.3	1	100.0
Elevated blood pressure	1	0.3	1	100.0
Haematuria	1	0.3	1	100.0
Limited function/disability urinary	1	0.3	1	100.0
Urinary disease, other	1	0.3	1	100.0
	=====		=====		=====		=====	
	290		284		0		6	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

Table 7.3: Medication status by individual problem managed - Allopurinol Jan05-Dec05

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol		New n	% of meds for specific prob	Continued n	% of meds for specific prob
Gout	236	72.4		27	11.4	209	88.6
Prescription all*	32	9.8		2	6.3	30	93.8
Endocrine/metabolic/nutritional disease, other	15	4.6		2	13.3	13	86.7
Hypertension*	7	2.1		.	.	7	100.0
Diabetes*	5	1.5		.	.	5	100.0
Arthritis (excl. OA and rheumatoid)*	4	1.2		1	25.0	3	75.0
Preventive immun/vacc/meds-all*	4	1.2		.	.	4	100.0
Urinary calculus	3	0.9		.	.	3	100.0
Osteoarthritis*	2	0.6		1	50.0	1	50.0
Limited function/disability NOS	1	0.3		.	.	1	100.0
General symptom/complaint, other	1	0.3		.	.	1	100.0
Benign/uncertain neoplasm blood/lymph	1	0.3		.	.	1	100.0
Blood/lymph/spleen disease, other	1	0.3		.	.	1	100.0
Oesophagus disease	1	0.3		.	.	1	100.0
Back complaint*	1	0.3		.	.	1	100.0
General check-up*	1	0.3		.	.	1	100.0
Abnormal test results*	1	0.3		1	100.0	.	.
Lipid disorders*	1	0.3		.	.	1	100.0
Limited function/disability cardiovascular	1	0.3		.	.	1	100.0
Rheumatic fever/heart disease	1	0.3		.	.	1	100.0
Heart failure	1	0.3		.	.	1	100.0
Elevated blood pressure	1	0.3		.	.	1	100.0
Joint symptom/complaint NOS	1	0.3		1	100.0	.	.
Haematuria	1	0.3		.	.	1	100.0
Limited function/disability urinary	1	0.3		.	.	1	100.0
Urinary disease, other	1	0.3		.	.	1	100.0
Prostatitis/seminal vesiculitis	1	0.3		1	100.0	.	.
	=====			===		=====	
	326			36		290	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

Table 7.4: Prescribed regimen** by individual problem managed for each generic
 - Allopurinol Jan05-Dec05

Generic	Problem label	n meds	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	Limited function/disability NOS	1	10	mg	3	daily	0.31
	General symptom/complaint, other	1	300	mg	1	daily	0.31
	Benign/uncertain neoplasm blood/lymph	1	300	mg	1	daily	0.31
	Blood/lymph/spleen disease, other	1	300	mg	1	daily	0.31
	Oesophagus disease	1	300	mg	1	daily	0.31
	Arthritis (excl. OA and rheumatoid)*	1	100	mg	1	daily	0.31
	Arthritis (excl. OA and rheumatoid)*	3	300	mg	1	daily	0.92
	Back complaint*	1	300	mg	1	daily	0.31
	General check-up*	1	300	mg	1	daily	0.31
	Hypertension*	1	0.31
	Hypertension*	1	.	.	1	daily	0.31
	Hypertension*	4	300	mg	1	daily	1.23
	Hypertension*	1	300	mg	2	daily	0.31
	Preventive immun/vacc/meds-all*	1	150	mg	1	daily	0.31
	Preventive immun/vacc/meds-all*	3	300	mg	1	daily	0.92
	Osteoarthritis*	1	100	mg	1	daily	0.31
	Osteoarthritis*	1	300	mg	1	daily	0.31
	Prescription all*	2	0.61
	Prescription all*	1	100	mg	1	daily	0.31
	Prescription all*	1	100	mg	2	daily	0.31
	Prescription all*	1	150	mg	1	daily	0.31
	Prescription all*	1	200	mg	1	daily	0.31
	Prescription all*	26	300	mg	1	daily	7.98
	Diabetes*	1	100	mg	1	daily	0.31
	Diabetes*	4	300	mg	1	daily	1.23
	Abnormal test results*	1	100	mg	1	daily	0.31
	Lipid disorders*	1	100	mg	1	daily	0.31
	Limited function/disability cardiovascular	1	300	mg	1	daily	0.31
	Rheumatic fever/heart disease	1	300	mg	1	daily	0.31
	Heart failure	1	100	mg	1	daily	0.31
	Elevated blood pressure	1	300	mg	.	.	0.31
Joint symptom/complaint NOS	1	100	mg	1	daily	0.31	
Gout	4	1.23	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.4: Prescribed regimen** by individual problem managed for each generic
- Allopurinol Jan05-Dec05

Generic	Problem label	n meds	Dose	Units	Quantity	Frequency	% of generic group
	Gout	2	.		1	daily	0.61
	Gout	1	50	mg	.		0.31
	Gout	1	50	mg	1	daily	0.31
	Gout	44	100	mg	1	daily	13.50
	Gout	5	100	mg	2	daily	1.53
	Gout	3	150	mg	1	daily	0.92
	Gout	18	200	mg	1	daily	5.52
	Gout	1	200	mg	2	daily	0.31
	Gout	2	300	mg	.		0.61
	Gout	152	300	mg	1	daily	46.63
	Gout	1	300	mg	2	daily	0.31
	Gout	1	400	mg	1	daily	0.31
	Gout	1	600	mg	1	daily	0.31
	Endocrine/metabolic/nutritional disease, other	4	100	mg	1	daily	1.23
	Endocrine/metabolic/nutritional disease, other	11	300	mg	1	daily	3.37
	Haematuria	1	300	mg	1	daily	0.31
	Limited function/disability urinary	1	100	mg	1	daily	0.31
	Urinary calculus	1	100	mg	1	daily	0.31
	Urinary calculus	2	300	mg	1	daily	0.61
	Urinary disease, other	1	300	mg	1	daily	0.31
	Prostatitis/seminal vesiculitis	1	.		1	daily	0.31

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.5: Prescribed daily dose** by individual problem managed for each generic
 - Allopurinol Jan05-Dec05

Generic	Problem label	n meds	Prescribed daily dose**	Units	% of generic group
Allopurinol	Limited function/disability NOS	1	30	mg	0.32
	General symptom/complaint, other	1	300	mg	0.32
	Benign/uncertain neoplasm blood/lymph	1	300	mg	0.32
	Blood/lymph/spleen disease, other	1	300	mg	0.32
	Oesophagus disease	1	300	mg	0.32
	Arthritis (excl. OA and rheumatoid)*	1	100	mg	0.32
	Arthritis (excl. OA and rheumatoid)*	3	300	mg	0.96
	Back complaint*	1	300	mg	0.32
	General check-up*	1	300	mg	0.32
	Hypertension*	4	300	mg	1.29
	Hypertension*	1	600	mg	0.32
	Preventive immun/vacc/meds-all*	1	150	mg	0.32
	Preventive immun/vacc/meds-all*	3	300	mg	0.96
	Osteoarthritis*	1	100	mg	0.32
	Osteoarthritis*	1	300	mg	0.32
	Prescription all*	1	100	mg	0.32
	Prescription all*	1	150	mg	0.32
	Prescription all*	2	200	mg	0.64
	Prescription all*	26	300	mg	8.36
	Diabetes*	1	100	mg	0.32
	Diabetes*	4	300	mg	1.29
	Abnormal test results*	1	100	mg	0.32
	Lipid disorders*	1	100	mg	0.32
	Limited function/disability cardiovascular	1	300	mg	0.32
	Rheumatic fever/heart disease	1	300	mg	0.32
	Heart failure	1	100	mg	0.32
	Joint symptom/complaint NOS	1	100	mg	0.32
	Gout	1	50	mg	0.32
	Gout	44	100	mg	14.15
	Gout	3	150	mg	0.96
Gout	23	200	mg	7.40	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 7.5: Prescribed daily dose** by individual problem managed for each generic
 - Allopurinol Jan05-Dec05

Generic	Problem label	n meds	Prescribed daily dose**	Units	% of generic group
	Gout	152	300	mg	48.87
	Gout	2	400	mg	0.64
	Gout	2	600	mg	0.64
	Endocrine/metabolic/nutritional disease, other	4	100	mg	1.29
	Endocrine/metabolic/nutritional disease, other	11	300	mg	3.54
	Haematuria	1	300	mg	0.32
	Limited function/disability urinary	1	100	mg	0.32
	Urinary calculus	1	100	mg	0.32
	Urinary calculus	2	300	mg	0.64
	Urinary disease, other	1	300	mg	0.32

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 7.6: Average prescribed daily dose** by individual problem managed for each generic
 - Allopurinol Jan05-Dec05

Generic	Problem label	n	Mean		Median		Minimum		Maximum	
		meds	PDD	Measure	PDD	Measure	Measure	Measure	Measure	
Allopurinol	Limited function/disability NOS	1	30.0	mg	30	mg	30	mg	30	mg
	General symptom/complaint, other	1	300.0	mg	300	mg	300	mg	300	mg
	Benign/uncertain neoplasm blood/lymph	1	300.0	mg	300	mg	300	mg	300	mg
	Blood/lymph/spleen disease, other	1	300.0	mg	300	mg	300	mg	300	mg
	Oesophagus disease	1	300.0	mg	300	mg	300	mg	300	mg
	Arthritis (excl. OA and rheumatoid)*	4	250.0	mg	300	mg	100	mg	300	mg
	Back complaint*	1	300.0	mg	300	mg	300	mg	300	mg
	General check-up*	1	300.0	mg	300	mg	300	mg	300	mg
	Hypertension*	5	360.0	mg	300	mg	300	mg	600	mg
	Preventive immun/vacc/meds-all*	4	262.5	mg	300	mg	150	mg	300	mg
	Osteoarthritis*	2	200.0	mg	200	mg	100	mg	300	mg
	Prescription all*	30	281.7	mg	300	mg	100	mg	300	mg
	Diabetes*	5	260.0	mg	300	mg	100	mg	300	mg
	Abnormal test results*	1	100.0	mg	100	mg	100	mg	100	mg
	Lipid disorders*	1	100.0	mg	100	mg	100	mg	100	mg
	Limited function/disability cardiovascular	1	300.0	mg	300	mg	300	mg	300	mg
	Rheumatic fever/heart disease	1	300.0	mg	300	mg	300	mg	300	mg
	Heart failure	1	100.0	mg	100	mg	100	mg	100	mg
	Joint symptom/complaint NOS	1	100.0	mg	100	mg	100	mg	100	mg
	Gout	227	251.5	mg	300	mg	50	mg	600	mg
	Endocrine/metabolic/nutritional disease, other	15	246.7	mg	300	mg	100	mg	300	mg
	Haematuria	1	300.0	mg	300	mg	300	mg	300	mg
	Limited function/disability urinary	1	100.0	mg	100	mg	100	mg	100	mg
Urinary calculus	3	233.3	mg	300	mg	100	mg	300	mg	
Urinary disease, other	1	300.0	mg	300	mg	300	mg	300	mg	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 05JUL11

Table 7.7: Average number of repeats by individual problem managed - Allopurinol Jan05-Dec05

Problem label	n meds	Mean repeats	Median repeats	Minimum	Maximum
Gout	202.00	1.9	2.0	0	5
Prescription all*	25.00	1.9	2.0	0	5
Endocrine/metabolic/nutritional disease, other	12.00	1.8	2.0	0	5
Arthritis (excl. OA and rheumatoid)*	4.00	2.0	2.0	2	2
Preventive immun/vacc/meds-all*	4.00	1.3	1.5	0	2
Hypertension*	3.00	2.0	2.0	2	2
Diabetes*	3.00	3.0	2.0	2	5
Urinary calculus	3.00	1.7	2.0	1	2
Osteoarthritis*	2.00	1.5	1.5	1	2
Limited function/disability NOS	1.00	2.0	2.0	2	2
General symptom/complaint, other	1.00	1.0	1.0	1	1
Benign/uncertain neoplasm blood/lymph	1.00	2.0	2.0	2	2
Oesophagus disease	1.00	2.0	2.0	2	2
Back complaint*	1.00	2.0	2.0	2	2
General check-up*	1.00	1.0	1.0	1	1
Abnormal test results*	1.00	0.0	0.0	0	0
Rheumatic fever/heart disease	1.00	2.0	2.0	2	2
Heart failure	1.00	2.0	2.0	2	2
Elevated blood pressure	1.00	1.0	1.0	1	1
Joint symptom/complaint NOS	1.00	2.0	2.0	2	2
Limited function/disability urinary	1.00	2.0	2.0	2	2
Urinary disease, other	1.00	2.0	2.0	2	2
Prostatitis/seminal vesiculitis	1.00	0.0	0.0	0	0

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).